Jan 04, 2019 12:18 JST

Source: Eisai

Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards
For Dealing with Viruses and Bacteria! Antimicrobial Barrier that Lasts for 1 Week

TOKYO, Jan 04, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received a "Nikkei Business Daily Awards for Superiority" for its Etak Antimicrobial Spray Alpha, which contains long-acting antimicrobial agent Etak, at the 2018 Nikkei Superior Products and Services Awards sponsored by Nikkei Inc.

Since 1982, the Nikkei Superior Products and Services Awards are awarded every year to superior new products and services, and this marks the 37th iteration of the awards. Without accepting applications for nomination, award recipients are selected from among the approximately 20,000 new products and services reported in The Nikkei, The Nikkei Business Daily, The Nikkei Marketing Journal, The Nikkei Veritas, Nikkei.com (the Nikkei's electronic edition) and the Nikkei Asian Review. For screening, products and services are comprehensively assessed across six aspects:

1) Excellence in technology development
2) Cost-effectiveness
3) Contribution to business performance
4) Growth potential
5) Uniqueness
6) Commercial impact and social impact.

Etak Antimicrobial Spray Alpha was selected for offering the concept of "long-acting antimicrobial action" in the anti-virus/bacteria product market and for developing a new customer segment in consideration of ease-of-use for child-raising families due to being non-alcohol, as well as for cost-performance by providing an antimicrobial effect that lasts for one week and with 250 ml can be used for approximately 800 pushes.

Etak Antimicrobial Spray Alpha was born from a previously unheard of concept of keeping viruses and bacteria at bay with an antimicrobial barrier. The product is a spray that contains Etak, a patented long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. Not only is it possible to eliminate viruses and bacteria by simply spraying the product, the antimicrobial component is bound to the spray area, providing an antimicrobial effect that lasts for one week even after drying.

Spraying Etak Antimicrobial Spray Alpha beforehand creates an antimicrobial barrier on various objects in the surrounding environment which keeps away viruses and bacteria. Spraying coats, gloves and bags before going out will repel viruses and bacteria, and also helps prevent the spread of viruses and bacteria indoors via hands and objects. A single bottle of Etak Antimicrobial Spray Alpha can be used in a variety of lifestyle scenes including on door knobs, tables, bedding, kitchen items such as counters, chopping boards and knives, as well as in bathrooms and toilets. In addition, the product is scentless and contains no alcohol, making it also ideal for children's items such as toys, as well as nursing care items.

Together with providing Etak Antimicrobial Spray Alpha to contribute to consumers who wish to keep viruses and bacteria at bay, Eisai remains committed to ensuring the delivery of products that satisfy the diversified needs of consumers and to further increasing the benefits provided to them.

Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
 
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
 
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
 
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
 
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
 
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
More Press release >>

Latest Press Release


More Latest Release >>